OssDsign
Slipp dessa annonser och få en massa andra godsaker med vårt
premiumabonnemang.
OssDsign publishes Annual Report 2023
REG
“We enter 2024 as a pure play orthobiologics company with full focus on the U.S. market, fortified with excellent clinical results and an expanded indication for OssDsign Catalyst®” said Morten Henneveld, CEO, OssDsign AB.
| Datum | 2024-06-04, kl 08:00 |
| Källa | Cision |